|
|
|
|
|
| |
Current
Issues - Newsletter
May 1998 |
|
| |
|
|
|
|
|
| |
Bioperine®:
New U.S. Patent
|
|
| |
| |
Sabinsa
Corporation was assigned a second patent on its trademarked
standardized black pepper extract, Bioperine(R), by the
U.S. Patents and Trademarks office.
The first patent on the use of Bioperine®
as an enhancer of nutrient bioavailability, (U.S. Patent
5,536,506) was issued in 1996. Patent 5,744,161 dated
April 28, 1998, covers the use of piperine as a bioavailability
enhancer for a broader range of nutritional supplements.
The salient features of the oral, topical and parenteral
compositions with piperine described in the patent,
include increased gastrointestinal absorption and improved
transfer of nutrients / biological compounds through
various biological membrane barriers in the body, as
well as enhanced systemic utilization of these compounds.
The patent also describes a new process for the extraction
and purification of piperine.
|
|
|
|
|
|
| |
lnula racemosa Potentiates Insulin Sensitivity |
|
| |
| |
Lack
of cellular sensitivity to insulin seriously impairs
therapeutic approaches to diabetes management. Inula
racemosa, used traditionally as a cardiotonic may
sensitize cells to insulin as surmised from studies
on animal models. Inula racemosa is therefore a potential
herbal alternative for the management of insulin resistant
diabetes.
Ref:
- Ind. J. Exp. Biol. (1995), 33(9):686-689.
|
|
|
|
|
|
| |
Nancy Mc Mohon, Executive Assistant to Dr. Majeed
|
|
| |
| |
 |
Nancy is involved
in most of the projects at the Corporate Office
and ensures its smooth day to day functioning.
Nancy joined the Sabinsa team in 1996, bringing
with her over 30 years of versatile experience
in various corporate settings. Having assisted
top management personnel for most of her career,
her office skills and 'people potential' are
great assets to Sabinsa Corporation. Over the
years, Nancy kept up with the technological
advancements in the modern office through business
training programs. Currently, she also heads
the Human Resources Department at Sabinsa Corporation.
|
|
|
|
|
|
|
| |
Boswellin®:
Antileukotrienes approach to Bronchial Asthma |
|
| |
| |
Recent
studies show that asthma, even in its mildest form,
is an inflammatory disease mediated by leukotrienes.
The use of treatments with antileukotrienes for this
condition is therefore being emphasized. Antileukotrienes
have been used with success in clinical trials in the
management of various models of asthma1.
Recently, the Food and
Drug Administration approved a "once-a-day asthma
pill", Singulair (montelukast sodium) for the prevention
and treatment of chronic asthma. This drug works by
blocking leukotrienes which are involved . in the inflammatory
processes associated with asthma2.
In the phytonutritional approach, boswellic acids (from
the gum resin of Boswellia serrata) are the most promising
antileukotrienes.
Boswellic acids were proven
in in vitro studies, to be the most potent amongst several
herbal extracts in inhibiting the classical component
pathway of the inflammatory response, producing 100%
inhibition at a concentration of 0.1 micromole3.
Boswellic acids appear to be specific inhibitors of
leukotriene formation, functioning by inhibiting the
activity of the enzymes which lead to their formation.
Boswellic acids are therefore effective in the prevention
and/or control of inflammatory processes, which are
typically characterized by increased leukotriene formation4.
In addition to this mechanism, boswellic acids were
found to decrease the activity of human leukocyte elastase
(HLE). Both leukotriene formation and HLE release are
increased during the progression of hypersensitivity-based
diseases, such as asthma. This dual inhibitory action
was found to be unique to boswellic acids. The reported
blockade of two proinflammatory enzymes by boswellic
acids could be the rationale for their anti-allergic
and anti-asthmatic activity5.
Sabinsa Corporation supplies
an extract of Boswellia serrata, Boswellin®,
standardized for 65% boswellic acids. Intensive research
is underway at Sabinsa to develop a once-a-day anti-asthma
formulation based on the leukotrienes inhibitory activity
of boswellic acids.
Ref.:
- Annals of Internal Medicine. 1997, 127:
472-480.
- Retail Pharmacy News, April 1998.
- Planta Medica, 1989. 55: 235-242.
- Planta Medica, 1991. 57(3): 203-207.
- J. Pharm. Exp. Ther, 1997. 281(1): 460-463.
|
|
|
|
|
|
| |
Dr.
Zahir Shah Akhunzada Visits South Asia |
|
| |
| |
Dr. Zahir Shah Akhunzada,
a research scientist at Sabinsa R &D, Princeton
NJ, recently visited South Asia. Dr. Akhunzada found
his visit to Sabinsa's associate company in India,
SAMI Labs Ltd., Bangalore, particularly useful,
as he is actively involved in developing Quality
Control procedures and validating test methods for
Sabinsa's wide range of nutritional products.
|
| |
While at
Sami, Dr. Akhunzada had the opportunity to work
with our team of specialized scientists at the state-of-the-art
Quality Control and Quality Assurance Laboratory
at Kunigal near Bangalore. Dr. Akhunzada also personally
inspected sourced raw materials at selected locations
in South Asia, for adherance to Sabinsa 's stringent
quality standards.
|
| Dr.
Akhunzada validates an assay method on the HPLC,
at the QC facility |
|
|
|
| |
|
|
| |
| "The information
presented in the "Current Issues" Newsletter
from Sabinsa Corporation is for informational purposes
only. It is abstracted from web and print media
sources. Readers are advised to refer to the original
sources for additional information". |
|
|
|
| |
|
|
|
